NCT05514119View on ClinicalTrials.gov

A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 17, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

December 1, 2024

Conditions
Liver Transplant
Interventions
DRUG

Fenofibrate

160mg once daily orally for 12 weeks

Trial Locations (1)

85254

Mayo Clinic Arizona, Phoenix

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05514119 - A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation | Biotech Hunter | Biotech Hunter